STOCK TITAN

Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director Richard H. Scheller received a grant of stock options covering 18,000 shares of common stock. The options have an exercise price of $23.58 per share and expire on June 7, 2036.

The option award vests and becomes fully exercisable on the earlier of the company’s 2027 annual stockholders meeting or June 8, 2027, as long as Scheller continues to serve the company through that vesting date. This is a compensation-related grant rather than an open‑market transaction.

Positive

  • None.

Negative

  • None.
Insider SCHELLER RICHARD H
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 18,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 18,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 18,000 options Stock Option (Right to Buy) granted to director
Exercise price $23.58 per share Conversion or exercise price of stock option
Underlying shares 18,000 shares Common Stock underlying granted options
Options after grant 18,000 options Total derivative securities following transaction
Option expiration date June 7, 2036 Expiration date of granted stock options
Vesting date outside meeting June 8, 2027 Alternative vesting date if earlier meeting not held
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 23.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-07T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual stockholders meeting financial
"the issuer's 2027 annual stockholders meeting"
vest financial
"The option shall vest and be fully exercisable"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SCHELLER RICHARD H

(Last)(First)(Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$23.5806/08/2026A18,000 (1)06/07/2036Common Stock18,000$018,000D
Explanation of Responses:
1. The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
/s/ Courtney Phillips, as attorney-in-fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Maze Therapeutics (MAZE) report for Richard H. Scheller?

Maze Therapeutics reported that director Richard H. Scheller received a grant of stock options for 18,000 shares of common stock. This is a compensation-related award, not an open-market trade, and represents a right to buy shares at a fixed exercise price.

How many Maze Therapeutics (MAZE) options were granted to Richard H. Scheller and at what price?

Richard H. Scheller was granted stock options covering 18,000 shares of Maze Therapeutics common stock. The options carry an exercise price of $23.58 per share, setting the price at which he can later purchase the underlying shares if he chooses to exercise.

When do Richard H. Scheller’s Maze Therapeutics (MAZE) stock options vest?

The stock options granted to Richard H. Scheller will vest and become fully exercisable on the earlier of Maze Therapeutics’ 2027 annual stockholders meeting or June 8, 2027. Vesting is conditioned on his continued service with the company through that vesting date.

When do the newly granted Maze Therapeutics (MAZE) options to Richard H. Scheller expire?

The granted stock options to Richard H. Scheller expire on June 7, 2036. After that expiration date, any unexercised portion of the options can no longer be used to purchase Maze Therapeutics common shares under this award.

Is Richard H. Scheller’s Maze Therapeutics (MAZE) option grant an open-market purchase or sale?

The transaction is a grant of stock options as compensation, not an open-market purchase or sale. It provides Scheller with the right to buy Maze Therapeutics shares at $23.58 in the future, subject to vesting and before expiration.